News

As part of the deal, Tesaro will receive rights to monospecific antibody drug candidates targeting TIM-3, LAG-3 and PD-1 and dual reactive antibody drug candidates targeting PD-1/TIM-3 and

SmartFactory is a single-use cGMP bio-manufacturing capacity, which will help Alvotech to rapidly expand its biosimilars business. Finesse’s customers will also have access to Alvogen’s commercial, FDA approved,

The company plans to submit a protocol to the US Food and Drug Administration (FDA) in the first half of 2014 for a Phase I/II clinical trial to

Ferrer is Alexza’s commercial partner for Adasuve in the EU, Latin America and the Commonwealth of Independent States countries. Ferrer is commercializing the product in Romania through a

Saama Sales Operations Solution for Life Science is an integrated data and analytics platform that supports the drug commercialization process by automating sales operations and analytics. As part

BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate (remogliflozin) for type 2 diabetes and non-alcoholic steatohepatitis (NASH). Remogliflozin is currently in Phase II

This facility has been reconfigured to provide for 30 semi-private rooms to give each clinical trial volunteer a more comfortable experience for extended in-house stays. This dedicated clinical

The trial will assess the clinical effects of riociguat in patients with pulmonary arterial hypertension (PAH) who show an insufficient response to treatment with phosphodiesterase-5 inhibitors (PDE-5i) either

The deal will see MedImmune contribute both funding and a post-doctoral scientist to work within the laboratory of Professor Kevin Brindle at the University of Cambridge in the